CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • December 24th, 2009 • Neurogen Corp • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 24th, 2009 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of December 23, 2009 (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Neurogen Corporation, a Delaware corporation (“Target”), and Registrar and Transfer Company, a New Jersey corporation, as Rights Agent (the “Rights Agent”) and as initial Merck CVR Registrar (as defined herein).
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • December 24th, 2009 • Neurogen Corp • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 24th, 2009 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of December 23, 2009 (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Neurogen Corporation, a Delaware corporation (“Target”), and Registrar and Transfer Company, a New Jersey corporation, as Rights Agent (the “Rights Agent”) and as initial Aplindore CVR Registrar (as defined herein).
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • December 24th, 2009 • Neurogen Corp • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 24th, 2009 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of December 23, 2009 (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Neurogen Corporation, a Delaware corporation (“Target”), and Registrar and Transfer Company, a New Jersey corporation, as Rights Agent (the “Rights Agent”) and as initial H3 CVR Registrar (as defined herein).
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • December 24th, 2009 • Neurogen Corp • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 24th, 2009 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of December 23, 2009 (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Neurogen Corporation, a Delaware corporation (“Target”), and Registrar and Transfer Company, a New Jersey corporation, as Rights Agent (the “Rights Agent”) and as initial Real Estate CVR Registrar (as defined herein).